These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1026816)

  • 1. A preliminary clinical trial of rifampicin in leprosy.
    Bhide MB; Desai AC; Ganapati R
    Lepr India; 1976 Oct; 48(4 Suppl):781-3. PubMed ID: 1026816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introductory rifampicin therapy in lepromatous leprosy: a six month follow-up study.
    Girdhar BK; Ramu G; Sreevatsa ; Desikan KV
    Lepr India; 1978 Jul; 50(3):363-70. PubMed ID: 359925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of single dose (1500 mg) rifampicin on infectivity of patients with lepromatous leprosy.
    Girdhar BK; Sreevatsa ; Desikan KV
    Lepr India; 1980 Jul; 52(3):359-65. PubMed ID: 7206633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial with rifampicin in the treatment of leprosy.
    Ghosh S; Hazra SK; Kundu S; Choudhury S
    Lepr India; 1976 Oct; 48(4 Suppl):775-80. PubMed ID: 800236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin (RFP) trial in lepromatous leprosy.
    Koticha KK; Pade SS; Chulawala RG; Juwatkar PS
    Lepr India; 1982 Jul; 54(3):441-7. PubMed ID: 6757577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persister M. leprae after introductory rifampicin followed by dapsone therapy.
    Sreevatsa ; Girdhar BK; Desikan KV
    Lepr India; 1981 Jul; 53(3):350-3. PubMed ID: 7278139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone.
    Gelber RH; Humphres RC; Fieldsteel AH
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent rifampicin therapy in lepromatous leprosy.
    Girdhar BK; Sreevatsa ; Desikan KV
    Lepr India; 1980 Jan; 52(1):89-96. PubMed ID: 6991816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of L-tetramisol associated with rifampicin in patients with lepromatous leprosy. L-tetramisol in patients with lepromatous leprosy].
    Galmarini M; Riera CM; Ripoll J; Orozco MA; Katz J
    Med Cutan Ibero Lat Am; 1978; 6(3-4):179-83. PubMed ID: 398916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.
    Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [2 cases of recurrence resistant to rifampicin in lepromatous leprosy].
    Cottenot F; Wallach D; Flageul B; Pennec J; Wastiaux K
    Ann Dermatol Venereol; 1983; 110(9):703-4. PubMed ID: 6660769
    [No Abstract]   [Full Text] [Related]  

  • 13. [Study on short-term clinical trial of R-77-3 [3-(4-cyclo-pentyl-l-piperazinyl) imino methyl rifamycin SV] by mouse foot-pad technique].
    Wang HY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Oct; 10(5):374-5. PubMed ID: 2978259
    [No Abstract]   [Full Text] [Related]  

  • 14. [In vitro immunologic changes in 4 patients with lepromatous leprosy treated for 1 year with rifampicin and sulfones and left untreated the following year].
    Saint-André P
    Acta Leprol; 1979; (76-77):301-2. PubMed ID: 121849
    [No Abstract]   [Full Text] [Related]  

  • 15. Controlled comparison of therapeutic effects of DDS in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy.
    Ghosh S; McDougall AC; Hazra SK; Yawalkar SJ
    Indian J Dermatol; 1981 Oct; 26(4):1-6. PubMed ID: 6754585
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group.
    Indian J Lepr; 1997; 69(2):121-9. PubMed ID: 9290963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient.
    Kar HK; Roy RG
    Indian J Lepr; 1984; 56(4):835-9. PubMed ID: 6549453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report.
    Katoch K; Sreevatsa ; Ramanathan U; Ramu G
    Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):1-9. PubMed ID: 2453596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.